triazoles has been researched along with enfuvirtide in 18 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (27.78) | 29.6817 |
2010's | 13 (72.22) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Stephenson, J | 1 |
Bellos, N; Cooper, DA; Dunne, MW; Fätkenheuer, G; Felstead, S; Hirschel, B; Hoepelman, AI; Konourina, I; Lampiris, H; Lazzarin, A; Mayer, H; Nelson, M; Raffi, F; Ridgway, C; Saag, M; Sullivan, JF; Tawadrous, M; Tebas, P; Trottier, B; van der Ryst, E; Westby, M | 1 |
Melby, T; Westby, M | 1 |
Arribas, JR | 1 |
Doms, RW; Tilton, JC | 1 |
McKinnell, JA; Saag, MS | 1 |
D'Avolio, A; Fuchs, D; Gisslén, M; Hagberg, L; Svennerholm, B; Verhofstede, C; Watson, V; Yilmaz, A | 1 |
Alencar, CS; Diaz, RS; Ferreira, S; Giret, MT; Nishiya, AS; Sabino, EC | 1 |
Chen, CH; Huang, L; Lai, WH | 1 |
Zhang, XQ | 1 |
Férir, G; Palmer, KE; Schols, D | 1 |
Back, DJ; Else, LJ; Khoo, SH; Taylor, S | 1 |
Antunes, F; Barroso, H; Bártolo, I; Borrego, P; Caixas, U; Calado, R; Cavaco-Silva, P; Doroana, M; Maltez, F; Marcelino, JM; Rocha, C; Taveira, N | 1 |
Peterson, K; Rowland-Jones, S | 1 |
Colby-Germinario, SP; Donahue, DA; Kramer, VG; Oliveira, M; Schader, SM; Singhroy, DN; Sloan, RD; Tressler, R; Wainberg, MA | 1 |
Cardoso, SW; Grinsztejn, B; Guimarães, ML; Morgado, MG; Passaes, CP; Pilotto, JH; Veloso, V | 1 |
Hanna, GJ; Krystal, M; Lataillade, M; Li, Z; Ray, N; Sun, Y; Zhou, N | 1 |
Bellazzi, LI; Bianco, C; Bruzzone, B; Colao, G; Corsi, P; De Luca, A; Monno, L; Pagano, G; Paolucci, S; Punzi, G; Rossetti, B; Setti, M; Zazzi, M | 1 |
7 review(s) available for triazoles and enfuvirtide
Article | Year |
---|---|
Inhibitors of viral entry.
Topics: Animals; Chemokines; Cyclohexanes; Drug Resistance, Viral; Enfuvirtide; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Peptide Fragments; Triazoles; Virus Attachment; Virus Internalization | 2009 |
[Role of the new molecules in antiretroviral therapy. Position of raltegravir].
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Darunavir; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Enfuvirtide; Forecasting; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; Humans; Maraviroc; Nitriles; Peptide Fragments; Pyridazines; Pyridines; Pyrimidines; Pyrones; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Sulfonamides; Triazoles | 2008 |
Entry inhibitors in the treatment of HIV-1 infection.
Topics: Cyclohexanes; Drug Resistance, Viral; Enfuvirtide; History, 20th Century; History, 21st Century; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Peptide Fragments; Triazoles | 2010 |
Novel drug classes: entry inhibitors [enfuvirtide, chemokine (C-C motif) receptor 5 antagonists].
Topics: CCR5 Receptor Antagonists; Cyclohexanes; Enfuvirtide; HIV; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Peptide Fragments; Piperazines; Pyrimidines; Salvage Therapy; Triazoles; Virus Internalization | 2009 |
HIV entry inhibitors: progress in development and application.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; CD4 Antigens; Cyclohexanes; Drug Resistance, Viral; Enfuvirtide; HIV Envelope Protein gp120; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Molecular Structure; Peptide Fragments; Receptors, CCR5; Receptors, Chemokine; Receptors, CXCR4; Triazoles | 2010 |
[The newest developments in anti-HIV-1 drugs].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; Drug Resistance, Viral; Enfuvirtide; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Maraviroc; Molecular Structure; Peptide Fragments; Pyrrolidinones; Raltegravir Potassium; Saquinavir; Triazoles; Virus Replication; Zidovudine | 2010 |
Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid).
Topics: Adenine; Adult; Amniotic Fluid; Anti-HIV Agents; Cyclohexanes; Enfuvirtide; Female; Fetal Blood; Fetus; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Maraviroc; Nevirapine; Organophosphonates; Peptide Fragments; Placenta; Pregnancy; Pregnancy Complications, Infectious; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Tenofovir; Triazoles; Viral Load; Zidovudine | 2011 |
1 trial(s) available for triazoles and enfuvirtide
Article | Year |
---|---|
Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy.
Topics: Adult; Albumins; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Central Nervous System Infections; Cross-Over Studies; Cyclohexanes; Enfuvirtide; Female; HIV Envelope Protein gp41; HIV Infections; HIV-1; Humans; Immunoglobulin G; Lopinavir; Male; Maraviroc; Middle Aged; Neopterin; Peptide Fragments; Polymerase Chain Reaction; Ritonavir; RNA, Viral; Triazoles; Viral Load; Viremia; Virus Replication | 2010 |
10 other study(ies) available for triazoles and enfuvirtide
Article | Year |
---|---|
Researchers explore new anti-HIV agents.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclic N-Oxides; Drugs, Investigational; Enfuvirtide; Furans; HIV; HIV Envelope Protein gp120; HIV Envelope Protein gp41; HIV Infections; HIV Integrase Inhibitors; Humans; Nitriles; Oximes; Peptide Fragments; Piperazines; Piperidines; Pyridazines; Pyridines; Pyrimidines; Reverse Transcriptase Inhibitors; Triazoles | 2002 |
Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.
Topics: Adult; Aged; Anti-Retroviral Agents; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Double-Blind Method; Drug Therapy, Combination; Enfuvirtide; Ethnicity; Female; Genotype; Hepatitis B; Hepatitis C; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Odds Ratio; Peptide Fragments; Receptors, CCR5; RNA, Viral; Transaminases; Treatment Outcome; Triazoles; Viral Load | 2008 |
Evaluation of primary resistance to HIV entry inhibitors among brazilian patients failing reverse transcriptase/protease inhibitors treatment reveal high prevalence of maraviroc resistance-related mutations.
Topics: Adult; Ambulatory Care Facilities; Anti-HIV Agents; Brazil; Cyclohexanes; DNA, Viral; Drug Resistance, Viral; Enfuvirtide; env Gene Products, Human Immunodeficiency Virus; Female; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Male; Maraviroc; Middle Aged; Molecular Sequence Data; Mutation, Missense; Peptide Fragments; Piperazines; Prevalence; Proviruses; Sequence Analysis, DNA; Treatment Failure; Triazoles | 2010 |
Synergistic activity profile of griffithsin in combination with tenofovir, maraviroc and enfuvirtide against HIV-1 clade C.
Topics: Adenine; Algal Proteins; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Cells, Cultured; Cyclohexanes; Drug Synergism; Enfuvirtide; Genotype; HIV Envelope Protein gp41; HIV-1; Humans; Lectins; Leukocytes, Mononuclear; Maraviroc; Microbial Sensitivity Tests; Organophosphonates; Peptide Fragments; Plant Lectins; Tenofovir; Triazoles | 2011 |
Baseline susceptibility of primary HIV-2 to entry inhibitors.
Topics: Amides; Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; Enfuvirtide; Female; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV-1; HIV-2; Humans; Inhibitory Concentration 50; Male; Maraviroc; Microbial Sensitivity Tests; Peptide Fragments; Quaternary Ammonium Compounds; Triazoles | 2012 |
Novel agents for the treatment of HIV-2 infection.
Topics: CCR5 Receptor Antagonists; Cyclohexanes; Enfuvirtide; Female; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV-2; Humans; Male; Maraviroc; Peptide Fragments; Triazoles | 2012 |
Maraviroc and other HIV-1 entry inhibitors exhibit a class-specific redistribution effect that results in increased extracellular viral load.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Benzylamines; Cell Line; Cyclams; Cyclohexanes; Cyclopropanes; DNA, Viral; Drug Resistance, Viral; Enfuvirtide; Heterocyclic Compounds; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Maraviroc; Peptide Fragments; Pyrrolidinones; Raltegravir Potassium; Receptors, CCR5; Receptors, CXCR4; RNA, Viral; Triazoles; Viral Load; Virus Internalization | 2012 |
Monitoring the emergence of resistance mutations in patients infected with HIV-1 under salvage therapy with raltegravir in Rio de Janeiro, Brazil: a follow-up study.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Brazil; CD4 Lymphocyte Count; Cyclohexanes; Drug Resistance, Viral; Enfuvirtide; Follow-Up Studies; Genotyping Techniques; HIV Envelope Protein gp41; HIV Infections; HIV Integrase; HIV Protease; HIV Reverse Transcriptase; HIV-1; Humans; Maraviroc; Mutation; Peptide Fragments; Prospective Studies; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Salvage Therapy; Treatment Outcome; Triazoles; Viral Load; Virus Replication | 2012 |
Activity of the HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068, against CD4-independent viruses and HIV-1 envelopes resistant to other entry inhibitors.
Topics: Anti-HIV Agents; Antibodies, Monoclonal; CCR5 Receptor Antagonists; CD4 Antigens; Cyclohexanes; Drug Resistance, Viral; Enfuvirtide; HEK293 Cells; HIV Envelope Protein gp120; HIV Envelope Protein gp41; HIV-1; Humans; Maraviroc; Organophosphates; Peptide Fragments; Piperazines; Prodrugs; Receptors, CCR5; Receptors, CXCR4; Receptors, Virus; Triazoles; Virus Internalization | 2013 |
Virological and immunological response to antiretroviral regimens containing maraviroc in HIV type 1-infected patients in clinical practice: role of different tropism testing results and of concomitant treatments.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Enfuvirtide; Female; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Peptide Fragments; Retrospective Studies; RNA, Viral; Survival; Triazoles; Viral Load; Viral Tropism | 2014 |